Document Detail

Induction chemotherapy in head and neck cancer patients followed by concomitant docetaxel-based radiochemotherapy.
MedLine Citation:
PMID:  20477856     Owner:  NLM     Status:  MEDLINE    
Concurrent chemoradiotherapy has become the standard of care for patients with inoperable squamous cell head and neck carcinoma. More recently, induction chemotherapy has been adopted as an approach in the management of these patients. We report the results of a phase II trial associating induction chemotherapy and concomitant chemoradiotherapy in a series of patients with inoperable squamous cell head and neck cancer. Twenty-nine patients with advanced squamous cell carcinoma ineligible for surgery were enrolled. Induction chemotherapy with docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2) every 21 days was administered for two cycles. Radiotherapy followed the induction phase. During radiotherapy, docetaxel was administered weekly at the dose of 33 mg/m(2) . Primary end point of the study was feasibility of treatment. Six (18%) patients failed to conclude the treatment schedule. Although response rates in evaluable patients were very high (disease control rate >90%), toxicities were a matter of concern. The reported treatment schedule proved infeasible. However, some modifications in ancillary therapies aimed at exploiting its efficacy could make it practicable.
M Mencoboni; F Grillo-Ruggieri; A Salami; F Scasso; L Rebella; A Grimaldi; M Dellepiane; G Moratti; A Bruzzone; F Spigno; R Ghio; M Figliomeni
Related Documents :
16983506 - A phase ii study of su5416 in patients with advanced or recurrent head and neck cancers.
19107946 - Quality-adjusted survival analysis of radiation therapy oncology group (rtog) 90-03: ph...
2431756 - Multidrug chemotherapy using bleomycin, methotrexate, and cisplatin combined with radic...
14602316 - Periodic pharyngolaryngoscopy detects early head and neck cancer and improves survival ...
15237266 - Human papillomavirus and extragenital in situ carcinoma.
15770836 - No aberrant methylation of neurofibromatosis 1 gene (nf1) promoter in pilocytic astrocy...
Publication Detail:
Type:  Clinical Trial, Phase II; Journal Article     Date:  2010-04-30
Journal Detail:
Title:  European journal of cancer care     Volume:  20     ISSN:  1365-2354     ISO Abbreviation:  Eur J Cancer Care (Engl)     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-06-07     Completed Date:  2011-09-15     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  9301979     Medline TA:  Eur J Cancer Care (Engl)     Country:  England    
Other Details:
Languages:  eng     Pagination:  503-7     Citation Subset:  N    
Copyright Information:
© 2010 Blackwell Publishing Ltd.
Oncology Unit, Villa Scassi Hospital, ASL3 Genovese, Corso Onofrio Scassi, Genoa, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma / drug therapy*,  radiotherapy*
Carcinoma, Squamous Cell
Cisplatin / administration & dosage
Combined Modality Therapy / methods
Head and Neck Neoplasms / drug therapy*,  radiotherapy*
Middle Aged
Neoplasms, Squamous Cell / drug therapy*,  radiotherapy*
Remission Induction / methods
Taxoids / administration & dosage
Reg. No./Substance:
0/Taxoids; 15663-27-1/Cisplatin; 15H5577CQD/docetaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  'Listening to Patients': what is the value of age-appropriate care to teenagers and young adults wit...
Next Document:  Needs for everyday life support for brain tumour patients' relatives: systematic literature review.